Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia
Open Access
- 30 July 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 35 (1) , 2339440
Abstract
Oral systemic and injectable biologic treatments are available in Australia to treat moderate to severe psoriasis. To examine how patients and dermatologists in Australia choose between oral and injectable treatments for psoriasis. In this discrete choice experiment (DCE), adults with moderate to severe psoriasis and dermatologists were asked to choose between 2 treatments labeled by mode of administration ('oral' or 'subcutaneous injection'), each with randomly assigned levels for 9 treatment attributes. Needle fear was rated by patients. Completed surveys from 178 patients and 43 dermatologists were included in the analysis. Symptom reduction, safety, and mode of administration were attributes found to have a significant impact on treatment choice; dosing frequency was a significant attribute for the injectable option. When treatment attributes were held equal, patients and dermatologists preferred oral versus injectable treatments for moderate disease. Patients with higher levels of needle fear were more likely to favor an oral treatment versus patients with lower levels of needle fear. Participation bias may limit the generalizability of these findings. Participants preferred oral over injectable treatment for moderate psoriasis. These findings corroborate the need for efficacious oral therapies to treat the disease.Keywords
This publication has 25 references indexed in Scilit:
- Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-AnalysisDermatology and Therapy, 2022
- Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global SurveyDermatology and Therapy, 2022
- Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-AnalysisDermatology and Therapy, 2022
- Pathophysiology, Clinical Presentation, and Treatment of PsoriasisJAMA, 2020
- Treatment Goals in Psoriasis: Which Outcomes Matter Most?American Journal of Clinical Dermatology, 2020
- A Guide to Measuring and Interpreting Attribute ImportanceThe Patient - Patient-Centered Outcomes Research, 2019
- Discrete Choice Experiments in Health Economics: Past, Present and FuturePharmacoEconomics, 2018
- Shared Decision Making in Psoriasis: A Systematic Review of Quantitative and Qualitative StudiesAmerican Journal of Clinical Dermatology, 2018
- Treatment preferences and treatment satisfaction among psoriasis patients: a systematic reviewArchives of Dermatological Research, 2018
- Thurstonian-Based Analyses: Past, Present, and Future UtilitiesPsychometrika, 2006